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A class of secreted poxvirus tumor necrosis factor (TNF)-binding
proteins has been isolated from Tanapox-infected cell superna-
tants. The inhibitor bound to a TNF-affinity column and was
identified as the product of the 2L gene. Sequence analysis of 2L
family members from other yatapoxviruses and swinepox virus
yielded no sequence homology to any known cellular gene. The
expressed Tanapox virus 2L protein bound to human TNF with high
affinity (Kd  43 pM) and exhibits an unusually slow off-rate.
However, 2L is unable to bind to a wide range of human TNF family
members. The 2L protein can inhibit human TNF from binding to
TNF receptors I and II as well as block TNF-induced cytolysis. Thus,
Tanapox virus 2L represents an inhibitor of human TNF and offers
a unique strategy with which to modulate TNF activity.
The tumor necrosis factor (TNF) superfamily of ligands playscritical roles in both adaptive and innate immunity. These
ligands form a trimeric structure and bind to members of the
TNF receptor (TNFR) superfamily that mediate the signaling
events that regulate diverse responses, particularly inflammation
and apoptosis (1). During a viral infection, TNF, the prototypic
ligand for the family, is induced as an early response of the
immune system to an invading pathogen (2). TNF is expressed
by activated macrophages as a membrane-associated ligand,
which subsequently is cleaved and secreted as a trimer. The
proinflammatory effects of TNF are mediated through the cell
surface TNFRI and, to a lesser extent, TNFRII (3). Binding of
the TNF trimer causes conformational reorganization of the
receptors and subsequent recruitment of signaling proteins such
as TNFR-associated factor 2 (TRAF2) and Fas-associated death
domain (FADD) (3). The TNFTNFR signal transduction path-
way is such an important aspect of the antiviral response that a
number of viruses have evolved targeted strategies to specifically
disrupt it.
Poxviruses employ a wide range of strategies to modulate,
avoid, or diminish the various antiviral immune responses,
including the secretion of cytokine- and chemokine-binding
proteins and the production of cytokine and growth factor
homologs (4–7). The best characterized of these strategies are
the secreted homologs of the TNFRs that most likely were
derived by the acquisition of an ancestral host TNFR cDNA and
subsequent deletion of the transmembrane domain and cyto-
plasmic tail (8). The first characterized viral homolog of TNFR
was the secreted T2 protein from Shope fibroma virus, which
binds both TNF and lymphotoxin- (LT-) just as its cellular
counterpart (9, 10). Deletion of the related T2 gene from
myxoma virus greatly attenuated the virus in vivo (11).
Other poxvirus-secreted TNFRs were described for monkey-
pox virus, variola virus, vaccinia virus, ectromelia virus, and
cowpox virus (4, 8, 12). Cowpox virus is atypical among poxvi-
ruses because it encodes multiple, unique, soluble TNFRs
designated as cytokine response modifier (Crm)B (13), CrmC
(14), CrmD (15), and CrmE (16). Each of these cowpox virus
TNFRs has some sequence similarity with cellular TNFRs but
differs with respect to its ligand-binding specificities.
The Yatapoxvirus genus of poxviruses are composed of Yaba-
like disease virus (YLDV), Tanapox virus (TPV), and Yaba
monkey tumor virus (YMTV). The Yatapoxviruses have a
restricted host range, infecting only primates including humans.
They produce a relatively mild, self-limiting infection in humans
and monkeys (17, 18). Sequencing of the genomes of two
members of the Yatapox genus, YLDV and YMTV, did not
reveal any obvious TNFR homologs (ref. 19; C.R.B., H. Amano,
Y. Ueda, T. Miyamura, T. Suzuki, X. Li, J.W.B., and G.M.,
unpublished results). Despite this, one member of the Yatapox
genus, TPV, has been shown to express a TNF-binding activity
that is detected in the supernatants of TPV infected cells (20).
TPV is 98% identical to YLDV at the nucleotide level and is
considered to be a strain of YLDV (19). We reasoned that if
YLDVTPV encode a secreted TNF inhibitor, it must be a
member of a unique protein family because the genomes do not
include any genes with similarity to the known TNFRs. Here, we
describe the identification and characterization of this high-
affinity TNF inhibitor secreted from TPV-infected cells, which
forms the prototypic member of a previously uncharacterized
class of pathogen-derived inhibitors for human TNF.
Materials and Methods
Reagents. Recombinant human TNF, murine TNF, human IL-2,
human IL-5, human lymphotoxin-, and human IFN- were
obtained from BioSource International (Camarillo, CA). Hu-
man TNFR1-Fc and human TNFR2-Fc were obtained from
Apotech (Lausanne, Switzerland).
Viruses. TPV was obtained from Joe Esposito (Centers for
Disease Control and Prevention, Atlanta), and YMTV (VR587)
was obtained from the American Type Culture Collection. TPV
was propagated on OMK cells at 37°C, and YMTV was grown on
CV1 cells at 34°C.
Preparation of Human TNF Column. A human TNF affinity column
was prepared by using Aminolink Plus coupling gel (Pierce)
following manufacturer protocol.
Purification and Sequencing of the TPV TNF-Binding Protein. OMK
cells were infected with TPV at a multiplicity of infection of 50,
and the cells were incubated at 37°C for 6 h. Cells were washed
three times with serum-free medium and then incubated further
for 18 h at 37°C in serum-free medium. The supernatants were
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collected and clarified by spinning for 30 min at 500  g (IEC
PR-6000; Damon Biotechnology, Needham, MA) followed by a
60-min centrifugation at 85,000  g. The clarified supernatant
was dialyzed overnight against deionized water at 4°C. The TPV
supernatants then were applied to the human TNF affinity
column at a rate of 1 mlmin. The column was washed with PBS,
pH 7.4, and the TPV-2L protein was eluted with 0.2 M acetic
acid. The acetic acid was neutralized with the addition of 1 M
Tris base, and the material was dialyzed against PBS. SDS-gel
loading buffer (50 mM TrisCl, pH 6.8100 mM DTT2%
SDS0.1% bromophenol blue10% glycerol) (21) was added to
the eluant from the human TNF column and the sample was
boiled for 3 min. The proteins then were separated on a 10–20%
Tris-glycine precast gel (NOVEX, San Diego). The gel was
equilibrated with two 15-min washes with 25 mM Tris40 mM
norleucine, pH 9. Poly(vinylidene difluoride) (PVDF, 0.45 M;
Millipore) was washed in 100% methanol for 10 sec before
rinsing in deionized water. Proteins were transferred to the
PVDF membrane by electroblotting for 55 min at 1.5 mA
constant current per centimeter squared of PVDF membrane.
After transfer was complete, the blot was stained for 15 min with
Coomassie blue followed by destaining in 10% acetic acid and
50% methanol. The membrane was air-dried, a 38- to 45-kDa
protein band was excised, and N-terminal sequence analysis was
performed by using automated Edman degradation.
Construction of Recombinant Baculoviruses Expressing TPV 2L. TPV
gene 2L was amplified by PCR by using TAQ polymerase and
TPV DNA and primers that amplified the entire ORF. The 2L
gene subsequently was cloned into the TA cloning vector pCR2.1
(Invitrogen) to produce pCR2.1–2L. In addition, a Myc-His-
tagged version of TPV 2L was cloned by PCR by using TAQ
polymerase, TPV DNA, the forward primer 5-CCCAAGCT-
TCATGGATAAGTTACTATTATTTAGCAC-3 (with the
HindIII site underlined), and the reverse primer 5-CCGCTC-
GAGGGTTTCCGTCTTCTTCATCCTCTTC-3 (with the
XhoI site underlined), which change the endogenous stop codon
for 2L into a Gly residue. The resulting PCR product was cut with
the restriction enzymes HindIII and XhoI and cloned into
pcDNA3.1mycHis ver C (Invitrogen) to produce pcDNA-
2LmycHis. The genes 2L from pCR2.1–2L and 2LmycHis
from pcDNA-2LmycHis were cloned into pFastBac-1 (Invitro-
gen), and recombinant baculoviruses referred to as AcTPV-2L
and AcTPV-2LmycHis were produced by using the Bac-to-Bac
system following manufacturer protocol (Invitrogen).
Generation of TPV 2L Antibodies. TPV-2LmycHis was produced by
infecting SF-21 cells with AcTPV-2LmycHis in SF-900 II
serum-free medium (Invitrogen) and incubating at 27°C for 72 h.
The medium was collected and concentrated 10-fold on a
Nanosep 3K omega microconcentrator (Pall). The concentrated
medium was separated on a 12% polyacrylamide gel, and the
proteins were visualized with Coomassie blue. The band repre-
senting TPV-2LmycHis was excised washed with deionized
water and then placed in PBS. New Zealand White rabbits were
immunized four times with an emulsion of the polyacrylamide
gel fragment containing the TPV-2LmycHis protein and
Freund’s adjuvant. Antiserum was collected from the rabbits and
shown to recognize 2L protein by Western blotting.
Purification of TPV 2L. TPV-2L was produced by infecting SF-21
cells with AcTPV-2L in SF-900 II serum-free medium (Invitro-
gen) and incubating at 27°C for 72 h. The medium was collected
and dialyzed against PBS, pH 7.4, and concentrated by using a
Nanosep 3K omega microconcentrator (Pall). The supernatant
was passed over a human TNF affinity column at a rate of 1
mlmin. The column was washed with PBS, pH 7.4, and the
TPV-2L protein was eluted with 0.2 M acetic acid. The acetic
acid was neutralized with the addition of 1 M Tris base, and the
material was dialyzed against PBS.
Western Blot of 2L Family Members. Supernatants from YMTV,
TPV, or AcTPV-2L infected cells grown in serum-free medium
were concentrated 10-fold by using a Nanosep 3K omega mi-
croconcentrator (Pall). The concentrated proteins were mixed
with an equal volume of SDS-gel loading buffer (50 mM TrisCl,
pH 6.8100 mM DTT2% SDS0.1% bromophenol blue10%
glycerol) (21) and boiled for 5 min followed by separation of the
proteins on a 12% polyacrylamide gel. The proteins were
transferred from the gel to Hybond C nitrocellulose membrane
(Amersham Pharmacia) by using a semidry transfer apparatus
and transfer buffer (20% methanol25 mM Tris250 mM gly-
cine0.1% SDS). The membrane was blocked in TBST (140 mM
NaCl3 mM KCl24 mM Tris base, pH 7.40.2% Tween-20) 
5% powdered skim milk at 4°C overnight. A 1:10,000 dilution of
polyclonal rabbit anti-TPV-2L antiserum in TBST  5% pow-
dered skim milk was applied to the membrane and incubated at
room temperature for 1 h. The membrane was washed three
times for 5 min each with TBST followed by a 1-h incubation at
room temperature with goat anti-rabbit HRP (Jackson Immu-
noResearch) diluted in TBST  5% powdered skim milk. The
membrane was washed three times for 5 min each, and the signal
was detected by applying Chemiluminescence Reagent Plus
(Perkin–Elmer) and exposing the membrane to x-ray film (East-
man Kodak).
Biomolecular Interaction Analysis Using Surface Plasmon Resonance
(SPR). Approximately 500 response units (300 pgmm2) of puri-
fied baculovirus-produced TPV-2L was immobilized by using
standard amine-coupling chemistry (22) onto a CM-5 BIAcore
chip with a BIAcoreX biosensor (BIAcore, Uppsala). During the
association phase, TNF, IL-2, IL-5, IFN-, or LT- was diluted
in running buffer HBS-EP [10 mM Hepes, pH 7.4150 mM
NaCl3 mM EDTA0.005% polysorbate 20 (volvol)] and was
applied individually to the sensor chip in a 100-l volume at a
flow rate of 50 lmin. During the dissociation phase, HBS-EP
buffer was applied to the TPV-2L sensor chip at a flow rate of
50 lmin. After completion of an experiment, the TPV-2L
sensor chip was regenerated with 10 mM acetate, pH 4.0. To
correct for natural drift that occurs in a BIAcoreX biosensor, a
100-l injection of HBS-EP was made and the sensorgram
produced from this injection was subtracted from the sensor-
gram for the test proteins. The data were analyzed globally with
the BIAEVALUATION 3.0 software (BIAcore) by using a 1:1 mass
transport model.
Production of Rabbit TNF. Three 150-mm2 dishes of BGMK cells
were infected with either vaccinia virus Western Reserve strain
or a recombinant vaccinia virus expressing rabbit TNF (23) in
serum-free medium and incubated at 37°C for 3 days. The
supernatants from the cells were isolated and concentrated
10-fold on a Nanosep 3K omega microconcentrator (Pall).
Inhibition of TNF Binding to TNFR1 and TNFR2 by TPV-2L. ELISA
plates were coated with mouse anti-human IgG antibody (5
gml in 50 mM sodium carbonate, pH 9.6) for 16 h at 37°C
followed by blocking with PBS containing 4% powdered skim
milk and 0.5% Tween 20 for 1 h at 37°C. The plates were
incubated with hTNFR1-Fc or hTNFR2-Fc at 0.5 gml for 1 h
at 37°C in 100 l of incubation buffer followed by the addition
of Flag-hTNF or Flag-muTNF at 300 ngml (5 nM trimer)
premixed with varying amounts of TVP-2L mycHis (5 gml,
i.e., 125 nM and 2-fold dilutions). After a 1-h incubation at 37°C,
biotinylated anti-Flag M2 antibody (0.5 gml; Sigma) was
added and incubated at 37°C for 1 h. The presence of TNF was
detected with the incubation of horseradish peroxidase-coupled
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streptavidin (1:4,000) (Jackson ImmunoResearch) for 1 h at
37°C, and the plates were washed, incubated with o-
phenylenediamine (Sigma), and read at 490 nm.
Cytolytic Assays. Mouse L929 cells in six-well plates were incu-
bated in 1 ml of medium containing 5 gml actinomycin D and
either 3.5 nM purified TPV-2L or 3.5 nM purified myxoma T7
protein (a gift of Viron Therapeutics, London, Ontario), or no
protein was added. The cells then were treated with increasing
concentrations of purified human TNF, mouse TNF, or super-
natants from wild-type or recombinant vaccinia virus expressing
rabbit TNF-infected cells. The cells were incubated for 16 h at
37°C followed by staining with 0.5% crystal violet in methanol
water (1:4) for 5 min. The plates were rinsed in deionized water
and allowed to air-dry before images were taken on an inverted
microscope.
Results
Identification and Characterization of the TNF-Binding Activity of TPV.
A previous report had suggested that TNF-binding protein was
detectable in the supernatants of TPV-infected cells (20). To
further characterize this activity, supernatants from TPV-
infected cells were applied to a human TNF affinity column and
proteins bound to the column were eluted and subjected to
N-terminal sequencing (Fig. 1a). A comparison of the deduced
N-terminal peptide sequence from the major eluted 45-kDa
protein with amino acid sequences in the Swissprot database
identified the putative TNF-binding protein as closely related to
the product of the YLDV gene 2L (Fig. 1b). An alignment of the
N-terminal peptide sequence with the YLDV gene 2L revealed
that a closely related version of the N-terminal peptide sequence
began immediately after the predicted signal sequence cleavage
site (Fig. 1b), suggesting that the mature secreted protein has a
cleavable signal sequence at the predicted location.
The YLDV gene 2L is 338 aa long and predicted to encode a
protein of 38.8 kDa with four potential N-linked glycosylation
sites (ref. 19; Fig. 1b). YLDV 2L has no significant sequence
homology to any cellular gene, including any known TNFRs,
TNFR-related proteins such as TAC-I and BAFF-R, or any
other TNF-binding proteins, indicating that this protein is a
member of a previously uncharacterized protein family. A low
level of sequence similarity to regions of the MHC class I heavy
chain 2 and 3 domains was identified in a 54-aa stretch of the
2L gene (ref. 19; Fig. 1b), but the significance of this domain
similarity is unclear.
To determine whether TPV encodes a close relative of the 2L
protein, we first used PCR primers based on the flanking
sequence of 2L from YLDV. YLDV and TPV are 98%
identical at the nucleotide level (19); therefore, we tested
whether PCR primers based on the YLDV sequence would
amplify the corresponding TPV sequence. We were able to
successfully PCR-amplify and sequence the TPV-2L gene or-
tholog and compare it with the other poxvirus 2L-like genes (Fig.
2; refs. 19, 24, and 25 and C.R.B., H.A., Y.U., T.M., T.S., X.L.,
J.W.B., and G.M., unpublished results). The four known 2L-
family orthologs from YLDV, YMTV, TPV, and swinepox
(SPV) share 31% amino acid identity, including six conserved
cysteine residues that likely form three pairs of disulfide bonds
(Fig. 2). However, there is considerable divergence between the
SPV003148 gene and the three yatapox 2L genes, making the
identification of predicted domains that might be critical for
TNF binding difficult by comparative sequence analysis alone.
TPV and YMTV Each Express and Secrete 2L Protein. To confirm that
TPV and YMTV express the predicted 2L protein, we produced
an antiserum against a mycHis-tagged version of TPV 2L
expressed from a baculovirus vector and used this antiserum in
Western blots to test for the presence of the 2L protein in the
supernatants of TPV- and YMTV-infected cells. In TPV-
infected cell supernatants, a 45-kDa protein was detected that
had a size similar to the TPV-2L protein produced by the
Fig. 1. TNF-binding activity is encoded by poxvirus orthologs of the YLDV 2L
gene. (a) A schematic of the purification and sequencing strategy used to
isolate the TNF-binding activity from TPV-infected cell supernatant. (b) Align-
ment of the YLDV 2L gene with the N-terminal sequence obtained from the
TPV TNF-binding protein (blue) and amino acids 185–238 of murine MHC class
I histocompatibility antigen H-2 Q5-k -chain (red). The predicted signal
sequence cleavage site is shown as well as four potential N-linked glycosyla-
tion sites.
Fig. 2. Alignment of the identified 2L orthologs from other poxviruses. An
alignment of the vTNF-BP family members from TPV (TPV-2L), YLDV-2L, YMTV
(YMTV-2L), and the two copies from SPV (SPV003 and SPV148). The blackened
boxes denote conserved cysteine residues.
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recombinant baculovirus, confirming that the 2L protein indeed
was expressed and secreted (Fig. 3a). In addition, a 37-kDa
protein was detected in the supernatants of YMTV-infected
cells, indicating that YMTV expresses a lower molecular mass
variant of 2L and that the antiserum raised against TPV 2L
crossreacts with YMTV 2L (Fig. 3a). The differences in molec-
ular mass between the TPV and YMTV 2L genes likely results
from differential glycosylation or processing of the two proteins.
In this regard, YMTV 2L ORF includes three potential N-linked
oligosaccharide sites whereas TPV 2L has four potential N-
linked oligosaccharide sites.
TPV-2L Exhibits High-Affinity Binding for Human TNF. Previous stud-
ies had indicated that a 38-kDa TPV protein (termed gp38) had
the ability to bind TNF, IL-2, IL-5, and IFN- (20, 26). Because
TPV-2L binds to a TNF column, as does TPV gp38 (20), it is
reasonable to presume that the gp38 protein previously de-
scribed might be TPV-2L. We therefore tested TPV-2L to
determine whether it possessed the ability to complex with
human TNF, IL-2, IL-5, and IFN- by using SPR to measure the
rates of association and dissociation between the ligands and
TPV-2L. Purified baculovirus produced TPV-2L (Fig. 3b) was
immobilized by amine-coupling on a BIAcore CM5 sensor chip,
and human TNF, IL-2, IL-5, and IFN- were tested for their
ability to bind to the 2L-chip. Five nanomoles of human TNF
exhibited a fast association rate followed by a very slow disso-
ciation rate with TPV-2L (Fig. 4a). In contrast, 75 nM human
IL-2, human IL-5 (Fig. 4a), or human IFN- (data not shown)
showed no detectable binding by SPR to TPV-2L. Therefore,
TPV-2L possesses the TNF-binding activity reported previously
for gp38 but lacks the other reported binding activities attributed
to this species.
A number of poxvirus-encoded soluble TNFR homologs have
the ability to complex with both TNF and LT- (8). To deter-
mine the binding specificity for TPV-2L, we tested the ability of
human LT- and murine TNF to bind to TPV-2L by SPR. Even
though human TNF binds to TPV-2L with high affinity, we were
unable to detect any interaction between TPV-2L and 75 nM
murine TNF (Fig. 4a). Similarly, 75 nM human LT- was unable
to bind to TPV-2L. In addition, TPV-2L was unable to bind to
the human TNF family members FasL, APRIL, CD40L,
TRAIL, EDA1, EDA2, BAFF, TL1A, Tweak, CD30L, 41BBL,
Light, GITRL, RNAKL, OX40L, or mCD27L (see Fig. 7, which
is published as supporting information on the PNAS web site,
www.pnas.org), suggesting that TPV-2L has a very narrow ligand
specificity that is restricted to human, and likely other primate,
TNFs. The tropism of TPV-2L binding to human TNF is
consistent with the tropism of TPV and YLDV, which normally
infect only primates, including humans.
To determine the kinetics of interaction between TPV-2L and
human TNF, SPR was performed by using varying concentra-
tions of human TNF applied to the TPV-2L sensor chip. TPV-2L
binds with high affinity to TNF with a Kd of 43 pM (Fig. 4b).
TPV-2L binds with a relatively fast association rate of 3.38 106
M1s1 and a very slow dissociation rate of 1.45  104 s1.
These data indicate that TPV-2L is a high-affinity binding
protein for human TNF but not for murine TNF, human LT-,
human IL-2, human IL-5, or human IFN-. Furthermore, the
2Lhuman TNF complex is particularly stable, with an estimated
half-life of 6 h on the BIAcore chip.
TPV-2L Blocks TNF Binding to TNFRI and TNFRII. To determine
whether TPV-2L could block the ability of human or murine
TNF to bind to the TNFRs TNFRI and TNFRII, a mycHis-
tagged version of TPV-2L was incubated with either Flag-tagged
human or murine TNF. The TPV-2LTNF mixture was applied
to ELISA plates coated with either TNFRI or TNFRII, and the
amount of TNF able to bind was quantified. Fig. 5 demonstrates
that TPV-2L is able to bind and inhibit human but not murine
TNF from binding to the TNFRs. TPV-2L inhibited the binding
of hTNF to its receptors with an IC50 of 10–20 nM (of monomer).
Because TNF was used at a concentration of 5 nM (of trimer),
this indicates that the estimated ratio of TNF and TPV-2L in the
complex may be close to 1:1 stoichiometry.
TPV-2L Inhibits the Activity of Human but Not Murine or Rabbit TNF.
To determine whether TPV-2L could inhibit the biological
activity of TNF, we carried out a cytotoxicity assay by using
Fig. 3. 2L is produced and secreted during TPV and YMTV infections. (a)
Supernatants from AcTPV-2L-infected SF-21 cells, TPV-infected OMK cells, or
YMTV-infected CV1 cells were concentrated 10-fold, and the proteins were
separated on a polyacrylamide gel. Proteins then were transferred to a
nitrocellulose membrane that subsequently was probed with rabbit poly-
clonal antibodies raised against the TPV-2LmycHis protein. (b) Supernatants
from AcTPV-2L-infected SF-21 cells were passed over a human TNF column.
Proteins specifically binding to the column were eluted in 0.2 M acetic acid and
subsequently separated on a polyacrylamide gel and visualized by Coomassie
blue staining.
Fig. 4. TPV-2L binds to human TNF with high affinity but not murine TNF or
human IL-2, IL-5, or LT-. TPV-2L was immobilized on one flow cell of a CM-5
BIAcore sensor chip whereas the other flow cell acted as a blank control
surface. Over the TPV-2L sensor chip was passed 100l of human TNF, IL-2, IL-5,
LT-, or murine TNF (a) or duplicate injections of 0.3, 0.9, 2.8, or 8.3 nM human
TNF at a flow rate of 50lmin (b). The amount of protein bound to the surface
was recorded as response units as a function of time. After completion of the
injection phase (arrow), the dissociation phase was monitored during the
injection of buffer alone (HBS-EP). The sensorgrams shown were normalized
by subtracting the control surface sensorgram and a blank injection sensor-
gram. The binding kinetics were determined by using BIAEVALUATION 3.0 and a 1:1
mass transport model to determine the rate of association (Kon), the rate of
dissociation (Koff), and the rate constant (Kd).
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murine L929 cells. The addition of human or murine TNF
induces murine L929 cells to undergo apoptosis (Fig. 6 a and b,
mock). Similarly, the addition of 3.5 nM purified T7 protein, an
IFN--binding protein from myxoma virus (27, 28), as a control
failed to inhibit TNF-induced apoptosis (Fig. 6a). In contrast, the
addition of 3.5 nM TPV-2L was sufficient to dramatically inhibit
cytolysis caused by 11 pM human TNF (Fig. 6a). It required a
30-fold molar excess of TPV-2L (3.5 nM) to TNF (110 pM) to
achieve inhibition of TNF-induced apoptosis (Fig. 6a).
The species specificity for TNF inhibition by 2L protein was
examined next. Murine TNF at a concentration of 1.1 pM was
unable to induce apoptosis of L929 cells (data not shown)
whereas 11 pM was sufficient, and 2L protein did not affect
either threshold. These data suggest that 3.5 nM TPV-2L cannot
inhibit 11 pM murine TNF. To test whether TPV-2L could
inhibit rabbit TNF, supernatants from cells infected with a
recombinant vaccinia virus, which secretes rabbit TNF into the
medium (23), was used to induce apoptosis of L929 cells. Fig. 6c
shows that titrated recombinant rabbit TNF induced apoptosis of
L929 cells, whereas control supernatants from a wild-type
vaccinia virus were unable to induce apoptosis (mock). The
addition of TPV-2L had no effect on the induction of apoptosis
triggered by any concentration of recombinant vaccinia virus
expressing rabbit TNF. These data are consistent with the
observation that TPV-2L possesses a high affinity and specificity
for human TNF.
Discussion
We have identified and characterized a high-affinity inhibitor for
human TNF encoded by the TPV gene 2L, with related family
members present in YLDV, YMTV, and SPV. Unlike other
poxvirus TNF-binding proteins, the protein encoded by TPV-2L
shows no homology to cellular TNFRs and, hence, is referred to
as vTNF-BP to denote its unique status. In fact, the only
sequence similarity present in TPV-2L is to cellular MHC class
I molecules, and this is restricted to a portion of the 2 and 3
domains. The 1 and 2 domains of MHC class I are responsible
for the peptide-binding pocket, and the 3 domain is responsible
for binding to 2-microglobulin (29). TPV-2L lacks a complete
2 or 3 domain, so it is unclear what significance, if any, this
apparent similarity might represent. It is interesting to speculate
that TPV-2L may have originated from the acquisition of a
cellular MHC class I molecule followed by extensive sequence
divergence, but it should be noted that the similarity between
MHC class I and TPV-2L is relatively low and is restricted to a
54-aa stretch exhibiting 33% identity.
The 2L orthologs map near the termini for each of TPV, YLD
(19), YMTV (C.R.B., H. Amano, Y. Ueda, T. Miyamura, T.
Suzuki, X. Li, J.W.B., and G.M., unpublished results), and SPV
(25). In SPV, the TPV-2L ortholog maps in the terminal inverted
repeat, so that each genome of SPV contains two identical copies
of the 2L ortholog, designated SPV003 and SPV148. In contrast,
only the last three to six codons at the C terminus of the 2L gene
at the left genomic end are found in the terminal inverted repeats
of TPV, YLD, and YMTV, indicating that only one functional
copy of vTNF-BP is present in each of these yatapoxvirus
genomes.
With the identification of a novel class of vTNF-BPs in the
yatapox and suipox genera, the importance of the TNF pathway
as a significant antipoxviral strategy is underscored. To date,
inhibitory proteins targeted against TNF have been identified in
all poxvirus genera, with the exception of the capripoxviruses
(30, 31) and molluscipoxviruses (32) (although molluscipoxvirus
could interfere with TNF signaling via the vFLIP molecules).
Whether capripoxviruses and molluscipoxviruses truly lack anti-
TNF strategies or whether, as the yatapoxviruses and suipoxvi-
ruses, they utilize anti-TNF strategies that have yet to be
characterized remains to be demonstrated.
TPV-2L binds to TNF with an 1:1 stoichiometry to human
TNF. However, these figures rely strongly on the way concen-
trations were determined. We also do not know whether TPV-2L
is a monomer, a dimer, or an oligomer although preliminary
Fig. 5. TPV-2L inhibits TNF binding to both TNFRI and TNFRII. The binding of
a fixed concentration of Flag-tagged human TNF (hTNF) (solid symbols) to
human TNFRI (hTNFR1) ( and ) or human TNFRII (hTNFR2) (F and E) was
inhibited by increasing amounts of TPV-2L. In contrast, binding of Flag-tagged
murine TNF (muTNF) (open symbols) was unaffected by TPV-2L.
Fig. 6. TPV-2L inhibits human but not murine or rabbit TNF. L929 cells were
treated with actinomycin D along with 11 pM, 110 pM, or 1.1 nM of either
human (a) or murine (b) TNF to induce apoptosis. The cells then were treated
immediately with PBS (mock), 3.5 nM purified myxoma T7 protein (mT7), or 3.5
nM purified TPV-2L. (c) L929 cells were treated with 0, 0.001, 0.01, or 0.1 l of
supernatants from wild-type vaccinia virus Western Reserve strain (mock) or
vaccinia virus expressing rabbit TNF in the presence (rTNFTPV-2L) or absence
(rTNF) of 3.5 nM TPV-2L. All cells then were incubated for 16 h, and cell viability
was determined by staining with crystal violet.
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evidence suggests a monomeric form. Currently, x-ray crystal-
lographic studies are underway to determine the precise stoi-
chiometry of the complex as well as the contact points between
TPV-2L and human TNF.
TPV-2L binds with a very high affinity, with a dissociation rate
constant of 43 pM. What is particularly striking about the
binding of TPV-2L to human TNF is the extremely slow rate of
dissociation. The SPR sensorgrams of TPV-2L binding to human
TNF shows negligible dissociation between TNF and TPV-2L.
Thus, TPV-2L exhibits the strongest interaction reported to date
between human TNF and any other characterized proteins. For
example, murine TNFRs and cowpox CrmC bind to murine TNF
with an affinity of200 pM (14). The TNF antagonists currently
in human clinical trials, infliximab (Remicade) and etanercept
(Enbrel), bind human TNF with affinities of 450 and 1,150 pM,
respectively (33).
Although TPV-2L binds to human TNF with high affinity, it
failed to interact with human IL-2, IL-5, IFN-, LT-, and
murine TNF at least as measured by SPR. These latter ligands
were tested at a 250-fold higher concentration than that used for
human TNF. It remains possible that the interaction between
TPV-2L and other cytokines is not detectable by SPR, but it is
worth noting that murine TNF could not be inhibited by TPV-2L
in an in vivo cytolysis assay, confirming the SPR-binding analysis.
Previous reports had identified a multicytokine-binding pro-
tein present in the supernatants of TPV-infected cells that
neutralized TNF, IL-2, IL-5, and IFN- (20, 26). These activities
were ascribed to the protein designated gp38, based on its
molecular mass of 38 kDa. We show here that TPV-2L is a
45-kDa protein that binds and inhibits TNF but lacks any
detectable IL-2, IL-5, or IFN- binding. There are a number of
possible reasons to explain the differing binding activities be-
tween the predicted TPV gp38 species and what we have
observed for TPV-2L. It is possible that within the supernatants
of TPV infected cells, there are several proteins of approxi-
mately the same size that contribute to the multicytokine-
binding activity, of which 2L is one. Alternatively, IL-2, IL-5, or
IFN- simply may not bind to TPV-2L under the conditions used
for SPR. However, crosslinking studies between IL-2 and
TPV-2L failed to show any detectable interaction between these
two proteins (D. Ricciuto, J.W.B., and G.M., data not shown).
We conclude that TNF binding and inhibition are properties of
TPV-2L but that the other cytokine-inhibitory properties orig-
inally reported for gp38 reside in other still-unidentified TPV
proteins.
In conclusion, we describe a high-affinity inhibitor for human
TNF expressed by the 2L gene of TPV. The 2L sequence is
unrelated to any known TNFR or inhibitor and, hence, repre-
sents a unique inhibitory mechanism for human TNF. Solving
the structure of the vTNF-BPTNF complex should prove
illuminating given its unusually long half-life, and vTNF-BP
should provide a useful model with which to devise anti-TNF
strategies for therapeutic purposes.
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